Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Refractory Mucosa-Associated Lymphoid Tissue Lymphoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 6 of 0 results

Testing effectiveness (Phase 2)Study completedNCT00052572
What this trial is testing

Ixabepilone in Treating Patients With Relapsed or Refractory Lymphoproliferative Disorders

Who this might be right for
LeukemiaLymphoma
Memorial Sloan Kettering Cancer Center 35
Not applicableActive Not RecruitingNCT01199562
What this trial is testing

Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant

Who this might be right for
Hematopoietic/Lymphoid CancerAccelerated Phase Chronic Myelogenous LeukemiaAcute Undifferentiated Leukemia+151 more
City of Hope Medical Center 153
Large-scale testing (Phase 3)Study completedNCT00003805
What this trial is testing

Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count

Who this might be right for
Bone Marrow SuppressionFever, Sweats, and Hot FlashesInfection+6 more
European Organisation for Research and Treatment of Cancer - EORTC 859
Early research (Phase 1)Study completedNCT00005967
What this trial is testing

Tipifarnib in Treating Patients With Advanced Hematologic Cancer

Who this might be right for
Chronic Myeloproliferative DisordersLeukemiaLymphoma+2 more
National Cancer Institute (NCI) 36
Large-scale testing (Phase 3)Looking for participantsNCT06082102
What this trial is testing

Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma

Who this might be right for
Relapsed/Refractory Marginal Zone Lymphoma
Beijing InnoCare Pharma Tech Co., Ltd. 324
Testing effectiveness (Phase 2)Looking for participantsNCT06905509
What this trial is testing

Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma

Who this might be right for
Recurrent Diffuse Large B-Cell LymphomaRecurrent Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedRecurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements+11 more
University of California, Davis
25